- Report
- June 2018
- 49 Pages
Global
From €3395EUR$3,495USD£2,928GBP
- Drug Pipelines
- November 2020
- 34 Pages
Global
From €3399EUR$3,500USD£2,933GBP
- Drug Pipelines
- September 2020
- 426 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- February 2022
- 87 Pages
Global
From €3200EUR$3,529USD£2,857GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Report
- August 2021
- 85 Pages
Global
From €3200EUR$3,529USD£2,857GBP
- Report
- October 2022
- 35 Pages
Global
From €3399EUR$3,500USD£2,933GBP
- Report
- June 2022
- 340 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- November 2021
- 620 Pages
Global
From €3885EUR$4,000USD£3,351GBP
The Hepatitis C Drug market is a subset of the larger Infectious Diseases Drugs market. It is composed of drugs used to treat the Hepatitis C virus, a contagious virus that can cause liver damage. These drugs are typically administered orally or intravenously and can be used to treat both acute and chronic infections. The drugs are designed to reduce the amount of virus in the body, reduce the risk of liver damage, and improve the quality of life for those infected.
The Hepatitis C Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Other companies, such as Mylan, Cipla, and Natco Pharma, also offer treatments for the virus. Show Less Read more
